|
306 Companies |
|
474 Products |
|
474 Products |
|
223 Mechanisms of Action |
|
25 Trials |
|
4911 News |
|
| «12345678910111213...9899» |
- | sterile N-Acetylcysteine / Generic mfg., acetylcysteine solution / Generic mfg.
Trial primary completion date: NAC in TB DIH: A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced Hepatitis (clinicaltrials.gov) - May 9, 2017
P2/3, N=100, Recruiting, Sponsor: University of Cape Town
Trial primary completion date: May 2017 --> Jan 2018
- | diacerein / Generic mfg.
Enrollment closed, Trial primary completion date: DGCLFT2DM: Efficacy Study of Diacerein on Glycemic Control and Liver Fat in Type 2 Diabetes Subjects (clinicaltrials.gov) - May 9, 2017
P3, N=84, Active, not recruiting, Sponsor: Universidade Federal do Rio de Janeiro
Trial primary completion date: May 2017 --> Jan 2018 Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Jan 2017
- || Enrollment change: RELIEF: Recompensation of Exacerbated Liver Insufficiency With Hyperbilirubinemia and/or Encephalopathy and/or Renal Failure (clinicaltrials.gov) - May 8, 2017
P=N/A, N=59, Completed, Sponsor: Baxter Healthcare Corporation
Recruiting --> Active, not recruiting | Trial primary completion date: Jul 2016 --> Jan 2017 N=172 --> 59
- | Biomarker, Trial primary completion date: Development of a Novel Biomarker for Liver Fibrosis (clinicaltrials.gov) - May 8, 2017
P=N/A, N=125, Recruiting, Sponsor: University of California, Los Angeles
N=172 --> 59 Trial primary completion date: Mar 2017 --> Mar 2018
- Phase classification: TACE Study-Liver Embolization Perfusion (VGH Radiology LIU) (clinicaltrials.gov) - May 8, 2017
P=N/A, N=40, Completed, Sponsor: University of British Columbia
Trial primary completion date: Mar 2017 --> Mar 2018 Phase classification: P1 --> P=N/A
- || Xalkori (crizotinib) / Pfizer
Enrollment change, Metastases: Hepatic Impairment Study For Crizotinib In Advanced Cancer Patients (clinicaltrials.gov) - May 8, 2017
P1, N=70, Completed, Sponsor: Pfizer
Phase classification: P1 --> P=N/A N=88 --> 70
- Trial completion, Enrollment change: Resveratrol for the Treatment of Non Alcoholic Fatty Liver Disease and Insulin Resistance in Overweight Adolescents (clinicaltrials.gov) - May 5, 2017
P2/3, N=10, Completed, Sponsor: University of Manitoba
N=88 --> 70 Recruiting --> Completed | N=60 --> 10
- | Trial completion, Trial primary completion date: Effect of Non-Alcoholic Steatohepatitis (NASH) on the Pharmacokinetics of 99mTechnetium-Mebrofenin (clinicaltrials.gov) - May 5, 2017
P1, N=21, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed | N=60 --> 10 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016
- ||| sorafenib / Generic mfg.
Trial completion: SUCCESS: Sorafenib Concomitantly Used With TACE (Transarterial Chemoembolization) in uHCC (Unresectable Hepatocellular Carcinoma) Patients in China (clinicaltrials.gov) - May 4, 2017
P=N/A, N=302, Completed, Sponsor: Bayer
Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jul 2016 Active, not recruiting --> Completed
- | entecavir / Generic mfg., lamivudine HBV / Generic mfg., lamivudine / Generic mfg.
Trial primary completion date: Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine (clinicaltrials.gov) - May 3, 2017
P3, N=180, Recruiting, Sponsor: Seoul National University Hospital
Active, not recruiting --> Completed Trial primary completion date: Dec 2016 --> Jun 2017
- | Peyona (caffeine citrate) / Chiesi
Trial initiation date, Trial primary completion date: NOCTUA: Inhibition of VAP-1 by Caffeine in Healthy Human Volunteers Study (clinicaltrials.gov) - May 3, 2017
P1, N=63, Not yet recruiting, Sponsor: University of Birmingham
Trial primary completion date: Dec 2016 --> Jun 2017 Initiation date: Mar 2016 --> Mar 2018 | Trial primary completion date: Sep 2016 --> Sep 2018
- | everolimus / Generic mfg.
Trial termination: Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC (clinicaltrials.gov) - May 3, 2017
P2, N=65, Terminated, Sponsor: Novartis Pharmaceuticals
Completed --> Terminated; The study was terminated due to low enrollment. This resulted in the study being underpowered and inconclusive.
- | Biomarker, Trial completion, Enrollment change: HASIPRO: Unknown Cause of Acute Liver Failure (clinicaltrials.gov) - May 3, 2017
P=N/A, N=72, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
This resulted in the study being underpowered and inconclusive. Recruiting --> Completed | N=100 --> 72
- | Trial primary completion date: Gastric- Versus Jejunal Feeding Tubes in Alcoholic Liver Diseases (clinicaltrials.gov) - May 3, 2017
P=N/A, N=40, Recruiting, Sponsor: University of Aarhus
Recruiting --> Completed | N=100 --> 72 Trial primary completion date: Jan 2017 --> Jun 2018
- | Trial completion, Adherence: Intervention to Improve HCV Treatment Uptake and Adherence in HIV/HCV Coinfection (clinicaltrials.gov) - May 2, 2017
P=N/A, N=85, Completed, Sponsor: Icahn School of Medicine at Mount Sinai
Trial primary completion date: Jan 2017 --> Jun 2018 Active, not recruiting --> Completed
- oprozomib (ONX 0912) / Amgen
Phase classification, Combination therapy, Metastases: Phase 1b/2 Study of Oprozomib in Combination With Sorafenib in Subjects With Advanced Hepatocellular Carcinoma (clinicaltrials.gov) - May 2, 2017
P1b/2, N=0, Withdrawn, Sponsor: Amgen
Active, not recruiting --> Completed Phase classification: P1/2 --> P1b/2
- | Enrollment change, Trial primary completion date: Microsphere Localization Using PET/MRI or PET/CT in Patients Following Radioembolization (clinicaltrials.gov) - May 1, 2017
P1, N=80, Recruiting, Sponsor: Washington University School of Medicine
Phase classification: P1/2 --> P1b/2 N=60 --> 80 | Trial primary completion date: Jun 2017 --> Jun 2018
- | pravastatin / Generic mfg., sorafenib / Generic mfg.
Trial completion, Trial primary completion date: PRODIGE 21t: Palliative Treatment of Hepatocellular Carcinoma in Patient With CHILD B Cirrhosis (clinicaltrials.gov) - May 1, 2017
P2, N=160, Completed, Sponsor: University Hospital, Bordeaux
N=60 --> 80 | Trial primary completion date: Jun 2017 --> Jun 2018 Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Apr 2017
- | Trial completion, Enrollment change, Trial primary completion date: Genetic Effect on Omega 3 Fatty Acids for the Treatment of Fatty Liver Disease (clinicaltrials.gov) - Apr 28, 2017
P=N/A, N=17, Completed, Sponsor: Yale University
Active, not recruiting --> Completed | Trial primary completion date: Nov 2016 --> Apr 2017 Recruiting --> Completed | N=120 --> 17 | Trial primary completion date: Mar 2018 --> Feb 2017
- | lamivudine HBV / Generic mfg., lamivudine / Generic mfg., adefovir dipivoxil / Generic mfg.
Enrollment change, Trial termination: A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma (clinicaltrials.gov) - Apr 28, 2017
P3, N=117, Terminated, Sponsor: National Health Research Institutes, Taiwan
Recruiting --> Completed | N=120 --> 17 | Trial primary completion date: Mar 2018 --> Feb 2017 N=309 --> 117 | Active, not recruiting --> Terminated; No cases enrollment
- | atorvastatin / Generic mfg.
Enrollment change, Trial initiation date, Trial primary completion date: Assessment of Endothelial Function in Patients With Non Alcoholic Fatty Liver Disease and the Impact of Statin Treatment (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=0, Withdrawn, Sponsor: Sheba Medical Center
N=309 --> 117 | Active, not recruiting --> Terminated; No cases enrollment N=150 --> 0 | Initiation date: Dec 2013 --> Dec 2015 | Trial primary completion date: Jul 2015 --> Dec 2015
- | Trial completion, Enrollment change, Trial primary completion date: The Role of Obstructive Sleep Apnea in Children With Fatty Liver Disease (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=1, Completed, Sponsor: Yale University
N=150 --> 0 | Initiation date: Dec 2013 --> Dec 2015 | Trial primary completion date: Jul 2015 --> Dec 2015 Recruiting --> Completed | N=15 --> 1 | Trial primary completion date: Jan 2018 --> Apr 2017
- | Trial completion, Enrollment change, Trial primary completion date: Mother-to-child Hepatitis D Transmission (clinicaltrials.gov) - Apr 27, 2017
P=N/A, N=54, Completed, Sponsor: Hopital Lariboisière
Recruiting --> Completed | N=15 --> 1 | Trial primary completion date: Jan 2018 --> Apr 2017 Recruiting --> Completed | N=40 --> 54 | Trial primary completion date: Jul 2017 --> Apr 2017
- | ribavirin / Generic mfg., abacavir / Generic mfg.
Trial completion, Trial primary completion date: Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment (clinicaltrials.gov) - Apr 27, 2017
P1, N=26, Completed, Sponsor: Johns Hopkins University
Recruiting --> Completed | N=40 --> 54 | Trial primary completion date: Jul 2017 --> Apr 2017 Recruiting --> Completed | Trial primary completion date: Mar 2012 --> Sep 2012
- ||||||| Zepatier (grazoprevir/elbasvir) / Merck (MSD)
Trial completion: Grazoprevir (MK-5172) and Elbasvir (MK-8742) Combination in Treatment-Na (clinicaltrials.gov) - Apr 27, 2017
P3, N=489, Completed, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed | Trial primary completion date: Mar 2012 --> Sep 2012 Active, not recruiting --> Completed
- ||||||| Hexaxim (DTaP-IPV-Hep B-Hib vaccine) / Sanofi
Trial completion, Trial primary completion date: DTaP-IPV-Hep B-PRP~T Combined Vaccine Versus DTaP-IPV//PRP~T Combined Vaccine + Hep B Vaccine in Hep B Primed Infants (clinicaltrials.gov) - Apr 26, 2017
P3, N=310, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016
- Nebido (testosterone undecanoate depot injection) / Bayer
Trial completion, Enrollment change: Testosterone Replacement in Non-alcoholic Steatohepatitis (TEREPINS) (clinicaltrials.gov) - Apr 26, 2017
P2, N=3, Completed, Sponsor: Sheffield Teaching Hospitals NHS Foundation Trust
Active, not recruiting --> Completed | Trial primary completion date: Jan 2016 --> Apr 2016 Recruiting --> Completed | N=10 --> 3
- | sorafenib / Generic mfg.
Biomarker, Trial completion, Trial initiation date, Trial primary completion date: Biomarker Analysis in Sorafenib Treated Hepatocellular Carcinoma Patients (clinicaltrials.gov) - Apr 26, 2017
P=N/A, N=100, Completed, Sponsor: Samsung Medical Center
Recruiting --> Completed | N=10 --> 3 Active, not recruiting --> Completed | Initiation date: Aug 2008 --> Jan 2010 | Trial primary completion date: Dec 2014 --> Jan 2014
- ||||||| ribavirin / Generic mfg.
Trial completion: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir Co-administered With Ribavirin (RBV) in Adults With Genotype 4 Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis (AGATE-1) (clinicaltrials.gov) - Apr 26, 2017
P3, N=185, Completed, Sponsor: AbbVie
Active, not recruiting --> Completed | Initiation date: Aug 2008 --> Jan 2010 | Trial primary completion date: Dec 2014 --> Jan 2014 Active, not recruiting --> Completed
- | Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
Phase classification: Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver (clinicaltrials.gov) - Apr 25, 2017
P=N/A, N=0, No Longer Available, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Phase classification: P2 --> P=N/A
- | Enrollment change, Trial termination, Trial primary completion date: Prevalence and Clinical Course of Chronic Hep B Infection in IBD and Rheumatologic Disease (clinicaltrials.gov) - Apr 25, 2017
P=N/A, N=430, Terminated, Sponsor: Chinese University of Hong Kong
Phase classification: P2 --> P=N/A N=90 --> 430 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Oct 2015; sample size recruited is not enough
- ||| Trial completion: Registry Study for Patients With Chronic HBV Receiving Nucleotide Therapy (clinicaltrials.gov) - Apr 24, 2017
P=N/A, N=54, Completed, Sponsor: Gilead Sciences
N=90 --> 430 | Recruiting --> Terminated | Trial primary completion date: Mar 2016 --> Oct 2015; sample size recruited is not enough Active, not recruiting --> Completed
- |||| Trial primary completion date: Long-Term Follow-Up Studies at Year 6, 7, 8, 9, 10: 2 Formulations of Combined Hepatitis A/B Vaccine Compared in Subjects Aged 12-15 Years (clinicaltrials.gov) - Apr 20, 2017
P3, N=244, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Trial primary completion date: Jul 2008 --> Jun 2004
- ||||||| Doptelet (avatrombopag) / SOBI
Trial completion, Enrollment change: Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure (clinicaltrials.gov) - Apr 20, 2017
P3, N=231, Completed, Sponsor: Eisai Inc.
Trial primary completion date: Jul 2008 --> Jun 2004 Recruiting --> Completed | N=300 --> 231
- | sorafenib / Generic mfg.
Enrollment change, Trial termination, Trial primary completion date, Metastases: HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) (clinicaltrials.gov) - Apr 19, 2017
P4, N=3, Terminated, Sponsor: Massachusetts General Hospital
Recruiting --> Completed | N=300 --> 231 N=20 --> 3 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Dec 2016; Slow Accrual
- | Biomarker, Trial completion: Identifying Changes in Blood (Potential Biomarkers) in Individuals With Drug-Induced Liver Injury (clinicaltrials.gov) - Apr 18, 2017
P=N/A, N=25, Completed, Sponsor: University of North Carolina, Chapel Hill
N=20 --> 3 | Recruiting --> Terminated | Trial primary completion date: Feb 2015 --> Dec 2016; Slow Accrual Recruiting --> Completed
- | Phase classification, Enrollment change: Safety, Metabolism, and Antioxidant Activity of Silymarin and Green Tea Extract in Patients With Chronic Hepatitis C (clinicaltrials.gov) - Apr 18, 2017
P1, N=28, Completed, Sponsor: University of North Carolina, Chapel Hill
Recruiting --> Completed Phase classification: P1/2 --> P1 | N=60 --> 28
- | Enrollment change, Trial primary completion date: Stratification of Patients With Chronic Liver Disease Using Multi Spectral CT (clinicaltrials.gov) - Apr 17, 2017
P=N/A, N=10, Completed, Sponsor: Massachusetts General Hospital
Phase classification: P1/2 --> P1 | N=60 --> 28 N=50 --> 10 | Trial primary completion date: May 2015 --> Oct 2016
- | Trial primary completion date: Glutamine Challenge as Predictor of Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt (TIPS) (clinicaltrials.gov) - Apr 16, 2017
P=N/A, N=3, Terminated, Sponsor: University of Arkansas
N=50 --> 10 | Trial primary completion date: May 2015 --> Oct 2016 Trial primary completion date: Feb 2017 --> Jan 2015
- | Trial primary completion date: Prognosis Factors of Cardiac Complications After Liver Transplantation (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=565, Active, not recruiting, Sponsor: Assistance Publique - Hôpitaux de Paris
Trial primary completion date: Feb 2017 --> Jan 2015 Trial primary completion date: Jan 2017 --> Apr 2017
- | Invanz (ertapenem) / Merck (MSD)
Trial primary completion date, Head-to-Head: Antibiotics for Klebsiella Liver Abscess Study (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=152, Recruiting, Sponsor: National University Hospital, Singapore
Trial primary completion date: Jan 2017 --> Apr 2017 Trial primary completion date: Aug 2015 --> Dec 2017
- ||| Sunvepra (asunaprevir) / BMS, Daklinza (daclatasvir) / BMS
Trial completion: Asunaprevir/Daclatasvir Safety Surveillance in Japanese Patients With Chronic Hepatitis C (clinicaltrials.gov) - Apr 14, 2017
P=N/A, N=2974, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Aug 2015 --> Dec 2017 Active, not recruiting --> Completed
- | Biomarker, Trial completion, Trial primary completion date: An Analysis of Urinary Proteases as Biomarkers for Hepatocellular Carcinoma-101423 (clinicaltrials.gov) - Apr 12, 2017
P=N/A, N=87, Completed, Sponsor: Vanderbilt University Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jan 2013
- | carotuximab IV (ENV-105) / Kairos Pharma
Trial primary completion date, Combination therapy, IO biomarker: Sorafenib and TRC105 in Hepatocellular Cancer (clinicaltrials.gov) - Apr 11, 2017
P1/2, N=27, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jan 2013 Trial primary completion date: Sep 2017 --> Jun 2016
- | Nplate (romiplostim) / Amgen, Kyowa Kirin
Enrollment change, Trial initiation date, Trial termination, Trial primary completion date: Romiplostim in Treating Hepatitis C-Infected Patients With Thrombocytopenia (clinicaltrials.gov) - Apr 11, 2017
P2, N=27, Terminated, Sponsor: University of Southern California
Trial primary completion date: Sep 2017 --> Jun 2016 N=36 --> 27 | Initiation date: Mar 2010 --> Jun 2010 | Suspended --> Terminated | Trial primary completion date: Apr 2016 --> Jul 2014; Approval of several new agents for the treatment of HCV infection would mitigate the future need for interferon HCV treatment
- | carotuximab IV (ENV-105) / Kairos Pharma
Enrollment closed, Enrollment change, Combination therapy, IO biomarker: Sorafenib and TRC105 in Hepatocellular Cancer (clinicaltrials.gov) - Apr 11, 2017
P1/2, N=27, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
N=36 --> 27 | Initiation date: Mar 2010 --> Jun 2010 | Suspended --> Terminated | Trial primary completion date: Apr 2016 --> Jul 2014; Approval of several new agents for the treatment of HCV infection would mitigate the future need for interferon HCV treatment Recruiting --> Active, not recruiting | N=44 --> 27
- | Omegaven (omega-3 long-chain polyunsaturated fatty acids) / Fresenius Kabi
Phase classification: Compassionate Use of Omegaven for Pediatric Patients With Parenteral Nutrition Associated Liver Disease (clinicaltrials.gov) - Apr 7, 2017
P=N/A, N=0, Available, Sponsor: Children's Hospital of Philadelphia
Recruiting --> Active, not recruiting | N=44 --> 27 Phase classification: P1 --> P=N/A
- | Victrelis (boceprevir) / Roche, Merck (MSD)
Phase classification: A Phase 2b, Safety and Efficacy Study of Boceprevir in Patients Coinfected With HIV and Hepatitis C (P05411 AM4) (clinicaltrials.gov) - Apr 7, 2017
P2b, N=99, Completed, Sponsor: Merck Sharp & Dohme Corp.
Phase classification: P1 --> P=N/A Phase classification: P2 --> P2b
- | pioglitazone / Generic mfg.
Trial completion, Trial primary completion date: VA NASH: Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment (clinicaltrials.gov) - Apr 7, 2017
P4, N=105, Completed, Sponsor: VA Office of Research and Development
Phase classification: P2 --> P2b Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2016
- || folate-tubulysin (EC1456) / Novartis
Enrollment change, Trial primary completion date, Metastases: Folic Acid-Tubulysin Conjugate EC1456 In Patients With Advanced Solid Tumors (clinicaltrials.gov) - Apr 7, 2017
P1, N=220, Recruiting, Sponsor: Endocyte
Active, not recruiting --> Completed | Trial primary completion date: Jun 2016 --> Sep 2016 N=30 --> 220 | Trial primary completion date: Dec 2016 --> Dec 2017